Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study

GlaxoSmithKline (GSK)

Status

Withdrawn

Conditions

Osteoarthritis

Treatments

Drug: Paracetamol 500 mg

Drug: Paracetamol 665 mg

Study type

Observational

Funder types

Industry

Identifiers

NCT02262702

RH01690 (Other Identifier)

202175

Details and patient eligibility

About

The aim of this observational study is to compare the use of an extended release paracetamol formulation with standard paracetamol in a cohort of Australian concessional patients with osteoarthritis (OA), to assess differences in prescribing patterns and patient compliance.

Full description

This retrospective analysis of physician prescribing data (long-term concessional cohort from the Medicare Australia PBS claims dataset for the time period 2008-2011 (4 years) will compare the use of extended release paracetamol (Panadol Osteo) with standard paracetamol 500mg in a cohort of Australian concessional patients with OA, to assess differences in prescribing patterns and patient compliance.

Sex

All

Ages

50 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants prescribed with a paracetamol product and categorized as a concessional patient
Participants with new episodes of OA (no history of OA paracetamol in previous 12 months) or suffering from chronic OA (history of OA paracetamol in the previous 12 months)

Exclusion criteria

Participants with Rheumatoid arthritis or other auto-immune inflammatory conditions
Participants receiving the following anti-rheumatoid therapies:Immunimodulators such as methotrexate, leflunamide and TNF blockers
Participants receiving treatment for cancer pain